MOUNJARO 2.5 mg/.5mL (Tirzepatide INJECTION, SOLUTION) 2.5 mg/.5mL

Tirzepatide, the active ingredient in MOUNJARO, is a GIP and GLP-1 receptor agonist. It selectively binds to and activates both the GIP and GLP-1 receptors, enhancing insulin secretion and reducing glucagon levels in a glucose-dependent manner. This helps to lower blood sugar levels and reduce body weight.

The recommended starting dosage of MOUNJARO is 2.5 mg injected subcutaneously once weekly. After 4 weeks, the dosage can be increased to 5 mg once weekly. Further dose increases can be made in 2.5 mg increments after at least 4 weeks on the current dose, as determined by the prescribing healthcare provider.

The safety of MOUNJARO during pregnancy or breastfeeding has not been established. It is important to consult with a healthcare provider to discuss the potential risks and benefits before using MOUNJARO in these situations.

To order MOUNJARO 2.5 mg/0.5mL from GNH India, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams across international markets. The team will ask you to confirm your trade or institutional credentials and will reply with pricing, availability, shipping, and the necessary import paperwork.

MOUNJARO is a dual GIP and GLP-1 receptor agonist, which distinguishes it from other GLP-1 receptor agonists that only target the GLP-1 receptor. This dual action may provide additional benefits in glycemic control and weight management compared to other medications in its class.

MOUNJARO should be stored in the refrigerator between 36°F to 46°F (2°C to 8°C). It can be stored at room temperature up to 86°F (30°C) for up to 21 days. Do not freeze MOUNJARO. Store it in the original carton to protect from light.

MOUNJARO is administered as a subcutaneous injection once weekly. The injection should be given in the abdomen, thigh, or upper arm, and the injection site should be rotated each week. It is important to follow the instructions provided by the healthcare provider and the patient information leaflet for proper administration.

The most serious risks associated with MOUNJARO include acute pancreatitis, severe hypoglycemia when used with insulin secretagogues or insulin, serious hypersensitivity reactions, acute kidney injury due to volume depletion, and severe gastrointestinal adverse reactions. Patients should be monitored for these risks and seek medical advice if they occur.

MOUNJARO should not be used by patients with a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, or a history of severe gastrointestinal disease. It is also not recommended for patients with severe gastroparesis. Always consult with a healthcare provider to determine if MOUNJARO is appropriate for you.